TABLE VIII.

Delay in pegfilgrastim prophylaxis for patients with the most common cancers^a

Cancer type	Regimen	Delayb at start of 1st cycle [n (%)]c
		Overall	Missing or unknown	None	1–5 Days	≥6 Days
Breast cancer	fec-d	20 (100)	0 (0)	19 (95)	1 (5)	0 (0)
	Other	33 (100)	0 (0)	31 (93.9)	1 (3)	1 (3)
	Regimen nr	0	—	—	—	—
Colorectal cancer	folfox6	3 (100)	0 (0)	3 (100)	0 (0)	0 (0)
	Other	2 (100)	0 (0)	2 (100)	0 (0)	0 (0)
	Regimen nr	0	—	—	—	—
Hodgkin lymphoma	abvd	4 (100)	0 (0)	4 (100)	0 (0)	0 (0)
	Other	0	—	—	—	—
	Regimen nr	0	—	—	—	—
Non-Hodgkin lymphoma	chop-r	5 (100)	0 (0)	5 (100)	0 (0)	0 (0)
	Other	1 (100)	0 (0)	1 (100)	0 (0)	0 (0)
	Regimen nr	0	—	—	—	—

^aIncludes only the uses adjudicated to be primary or secondary prophylaxis.

^bDelay at the start of a cycle is the number of days between the last day of intravenous chemotherapy and the day that granulocyte colony–stimulating factor (g-csf) was started (start date of g-csf, minus end date of chemotherapy, minus 1). No delay—that is, a zero result—indicates that g-csf was begun the day after the last dose of intravenous chemotherapy.

^cPercentages are calculated based on the number of delays for each cancer type and regimen.